Noxopharm develops and commercializes immuno oncology drugs for the treatment of cancer. Read more

Graham Kelly's photo - Founder & CEO of Noxopharm

Founder & CEO

Graham Kelly

CEO Approval Rating





PublicIndependent CompanyAustralian Securities ExchangeNOX









Missing a competitor? Contribute!

Genkyotex is perceived as one of Noxopharm's biggest rivals. Genkyotex was founded in 2006 in Saint-Julien-en-Genevois, Auvergne. Genkyotex is in the Biotechnology field. Genkyotex generates $71.2K less revenue than Noxopharm.

Noxxon Pharma is Noxopharm's #2 rival. Noxxon Pharma is a Public company that was founded in 1997 in Berlin, Berlin. Noxxon Pharma competes in the Biotechnology field. Compared to Noxopharm, Noxxon Pharma has 11 more employees.

Antabio is one of Noxopharm's top competitors. Antabio's headquarters is in Labege, Other, and was founded in 2009. Like Noxopharm, Antabio also operates in the Biotechnology industry. Antabio generates 601% of Noxopharm's revenue.


Help the Owler community know more

Competitor - 1/1

Is BioNTech a competitor of Noxopharm?

Noxopharm Quarterly and Annual Revenue

Coming soon for Noxopharm!

Annual Revenue

$ < 1M

Noxopharm's revenue is the ranked 18th among it's top 10 competitors. The top 10 competitors average 171.8M.

Noxopharm Acquisitions

No recent acquisitions found related to Noxopharm

Noxopharm Funding History

Since Noxopharm was founded in 2015, it has participated in 1 round of funding. In total Noxopharm has raised $10.8M. Noxopharm's funding round was on Mar 2018 for a total of $10.8M





Private Placement
Mar 2018

Since Noxopharm was founded in 2015, it has participated in 1 round of funding. In total Noxopharm has raised $10.8M. Noxopharm's funding round was on Mar 2018 for a total of $10.8M

Noxopharm Investments

No recent investments found related to Noxopharm

Noxopharm News

May 11, 2021Outsourcing-Pharma

Clinical study shows drug has COVID-19 treatment potential

Interim data reportedly indicates Noxopharmâs Veyonda could be effective in treating cytokine storm, ... See more »
May 7, 2021Proactive Investors

Noxopharm will progress to FDA approved breakthrough testing of Veyonda in first-line sarcoma treatment

CEP-2 will build on the encouraging outcomes of the CEP-1 pilot study where the chemo-enhancing effec... See more »
April 27, 2021FinanzNachrichten

Clinical Data Shows Noxopharm's Veyonda May Prevent Cytokine Storm

Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in... See more »
April 14, 2021MarketScreener

Files Septic Shock Treatment Patent for Veyonda

( New indication doubles the commercial opportunity See more »
March 18, 2021FinanzNachrichten

Noxopharm's NOXCOVID Trial Advances to Final Stage

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced that Veyonda... See more »
March 2, 2021Outsourcing-Pharma

Prostate cancer drug demonstrates major survival benefit

According to Noxopharm, a recent study shows combining its Veyonda drug and a radiopharmaceutical yie... See more »
January 13, 2021The Market Herald

Noxopharm (ASX:NOX) cleared to up dosage in COVID study

Noxopharm (NOX) has been cleared to up the dosage of its COVID-19...... See more »

Noxopharm Press Releases

November 20, 2019Business Wire India

Noxopharm's Clinical Programs Aiming to Unveil a Potential Blockbuster Drug in the Cancer Treatment Spectrum

Business Wire IndiaAustralia-based clinical stage drug development company, Noxopharm Limited (ASX: N... See more »
October 18, 2019StreetInsider

Potential for Fundamental Change in the Treatment of Brain Cancer

Noxopharm commences a research program pursuing a novel approach to the treatment of glioblastoma mul... See more »
September 17, 2019centralcharts

Veyonda® and Radiotherapy Profiled at Key Oncology Meeting

Research relating to Veyonda® in the treatment of advanced prostate cancer is to be included in a key... See more »
July 29, 2019GlobeNewswire

Appendix 4C- June 2019 Quarter

SYDNEY, Australia, July 29, 2019 (GLOBE NEWSWIRE) -- Noxopharm Limited (ASX: NOX) ('Noxopharm' or the... See more »
June 26, 2019StreetInsider

Conference Hears of Positive Interim Data from LuPIN Trial

Noxopharm Ltd (ASX: NOX) (‘Noxopharm’ or the ‘Company’) is pleased to report on positive interim clin... See more »
May 23, 2019GlobalNewswire

Promising Data Leads to Expansion of LuPIN Trial

SYDNEY, Australia, May 23, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX: NOX) ('Noxopharm' or the 'Company... See more »
February 6, 2019GlobeNewswire

Combination of Veyonda® + Radiotherapy Delivers Clinical Benefits In Noxopharm's DARRT-1 Interim Results

SYDNEY, Australia, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX: NOX) announces interim (12-week)... See more »

Social Media

Noxopharm Headquarters

Po Box 824

Sydney, New South Wales2074


Driving Directions »

Trending Companies

Noxopharm Summary



Noxopharm develops and commercializes immuno oncology drugs for the treatment of cancer. Noxopharm was founded in 2015. Noxopharm's headquarters is located in Sydney, New South Wales, AU 2074. It has raised 10.8M in 1 round. The latest round was in Ma...


Noxopharm's Founder & CEO, Graham Kelly, currently has an approval rating of 85%. Noxopharm's primary competitors are Genkyotex, Noxxon Pharma & Antabio.

Frequently Asked Questions about Noxopharm

  1. When was Noxopharm founded?

    Noxopharm was founded in 2015
  2. Who is Noxopharm's CEO?

    Noxopharm's CEO is Graham Kelly
  3. How much revenue does Noxopharm generate?

    Noxopharm generates $ < 1M in revenue
  4. How much funding does Noxopharm have?

    Noxopharm has historically raised $10.8M in funding
  1. Where is Noxopharm's headquarters?

    Noxopharm's headquarters is in Sydney New South Wales, AU
  2. How many employees does Noxopharm have?

    Noxopharm has 0 employees
  3. What sector does Noxopharm operate in?

    Noxopharm is in Biotechnology, Pharmaceuticals
  4. Who are Noxopharm's competitors?

    Noxopharm's top competitors are Genkyotex, Noxxon Pharma, Antabio